Fundz

Cue Biopharma Appoints Lucinda Warren as Chief Business Officer

PUBLIC · CUESep 09, 2024

Company

Cue Biopharma

BostonBiotechnologyHealth CareTherapeutics

Description

Cue Biopharma, Inc. has appointed Lucinda Warren as chief business officer (CBO). With extensive experience in strategic transactions, portfolio optimization, and alliance management, Lucinda Warren will play a pivotal role in advancing Cue Biopharma’s core corporate objectives following the company’s recent business restructuring and autoimmune program prioritization.

Quick answer

Cue Biopharma Appoints Lucinda Warren as Chief Business Officer (September 9, 2024). Cue Biopharma is based in Boston, Massachusetts, United States.

What did Cue Biopharma announce on September 9, 2024?
Cue Biopharma, Inc. has appointed Lucinda Warren as chief business officer (CBO). With extensive experience in strategic transactions, portfolio optimization, and alliance management, Lucinda Warren will play a pivotal role in advancing Cue Biopharma’s core corporate objectives following the company’s recent business restructuring and autoimmune program prioritization.
What does Cue Biopharma do?
Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease.
Where is Cue Biopharma based?
Cue Biopharma is based in Boston, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
AAVantgarde Bio (September 9, 2024), Solu Therapeutics (September 10, 2024), Tyra Biosciences (September 10, 2024) and Alchemab Therapeutics (September 12, 2024) also announced leadership changes within 45 days of Cue Biopharma.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Cue Biopharma, and when

A new leader at Cue Biopharma brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Cue Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cue Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cue Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cue Biopharma

Location

Boston, Massachusetts, United States

About

Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cue Biopharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Usman
Senior decision-maker at this company
••••••••@••••••••

See Usman's verified email →

Andrey
Senior decision-maker at this company
••••••••@••••••••

See Andrey's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Cue Biopharma's next move

Learn about Strategic plan

Cue Biopharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.